This study follows 11 people who previously received a gene therapy called Cal-1 for HIV. The goal is to watch for any delayed side effects over many years. Researchers will also check whether the modified cells are still present and active in the blood. It is a safety-only study…
Sponsor: Calimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC